- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | iSpecimen verzeichnet Umsatzrückgang und Verlust im letzten Quartal | 1 | IT BOLTWISE | ||
| 14.04. | iSpecimen Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 26.03. | iSpecimen Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 11.03. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | iSpecimen Inc.: iSpecimen Secures Suppliers for COVID-style hMPV Outbreak | 439 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus... ► Artikel lesen | |
| 16.01. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.12.24 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | iSpecimen expands cancer biospecimen services for research | 3 | Investing.com | ||
| 20.12.24 | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 355 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12.24 | iSpecimen Up on Positive Results From NDQ | 2 | Baystreet.ca | ||
| 13.12.24 | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 910 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12.24 | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 306 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen appoints Robert Lim as CEO | 1 | Seeking Alpha | ||
| 12.12.24 | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 527 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11.24 | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 303 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 07.11.24 | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 67,69 | -0,69 % | Illumina Aktie: Harter Brocken zu erwarten? | Illumina verzeichnet deutliche Kursverluste, während Analysten gespaltene Meinungen zur Zukunft des Genforschungsspezialisten haben. Entscheidende Quartalszahlen stehen bevor. Die Illumina-Aktie setzt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 34,000 | -1,16 % | CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? | ||
| INTELLIA THERAPEUTICS | 7,064 | -1,64 % | Intellia Therapeutics shares up after Wolfe upgrade | ||
| EDITAS MEDICINE | 1,407 | +9,07 % | Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition | Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 93,08 | +0,22 % | Neurocrine Highlights INGREZZA's Long-Term Efficacy & Safety In Older Adults With Tardive Dyskinesia | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term... ► Artikel lesen | |
| BLUEBIRD BIO | 3,600 | -1,10 % | bluebird bio Aktie: Welche Strategie verspricht Erfolg? | Carlyle Group und SK Capital Partners akquirieren Gentherapie-Entwickler bluebird bio. Der Börsenrückzug ermöglicht dem Unternehmen, fernab des Kapitalmarkts seine Strategie neu zu justieren. Die Finanzmärkte... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 11,595 | -1,02 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| GALAPAGOS NV | 23,420 | +1,30 % | Galapagos NV: Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts | First U.S. patient dosed in ATALANTA-1 study of GLPG5101
Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,520 | -0,98 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer | - Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15... ► Artikel lesen | |
| TWIST BIOSCIENCE | 34,150 | -3,23 % | Twist Bioscience Aktie: Unternehmensausblick aktuell | Twist Bioscience, ein führendes Unternehmen im Bereich der synthetischen Biologie und Genomik, hat kürzlich bedeutende Initiativen zur Unterstützung der globalen akademischen Forschungsgemeinschaft... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,800 | +0,87 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
| REPLIGEN | 127,00 | -0,35 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2024 Financial Results | Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 6,448 | -1,13 % | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... ► Artikel lesen | |
| XBIOTECH | 2,560 | -2,29 % | XFRA 4XB: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PERSONALIS | 3,322 | -1,13 % | Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue | FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and... ► Artikel lesen |
Das Unternehmen ISPECIMEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.
